SuperworthSiga Technologies EPS SIGA
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.05
- Latest quarter, Q2 FY26
- $0.17
- −65% on a year earlier
- Fiscal year 2025
- $0.31
- −63% on the year before
Siga Technologies' earnings per share was −$0.05 over the twelve months to Jun 30, 2026, down 104% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.17, down 65% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.31 | −63% |
| FY2024 | $0.83 | −13% |
| FY2023 | $0.95 | +107% |
| FY2022 | $0.46 | −49% |
| FY2021 | $0.91 | +26% |
| FY2020 | $0.72 | n/a |
| FY2019 | −$0.16 | −103% |
| FY2018 | $5.12 | n/a |
| FY2017 | −$0.79 | n/a |
| FY2016 | −$0.69 | n/a |
| FY2015 | −$0.72 | n/a |
| FY2014 | −$4.97 | n/a |
| FY2013 | −$0.32 | n/a |
| FY2012 | −$0.26 | −170% |
| FY2011 | $0.37 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.17 | −65% | −$0.05 | |
| Q1 FY26 | −$0.05 | n/a | $0.27 | |
| Q4 FY25 | −$0.08 | −113% | $0.31 | |
| Q3 FY25 | −$0.09 | −550% | $1.03 | |
| Q2 FY25 | $0.49 | +1533% | $1.14 | |
| Q1 FY25 | −$0.01 | −107% | $0.68 | |
| Q4 FY24 | $0.64 | −37% | $0.83 | |
| Q3 FY24 | $0.02 | n/a | $1.20 | |
| Q2 FY24 | $0.03 | n/a | $1.17 | |
| Q1 FY24 | $0.14 | n/a | $1.10 | |
| Q4 FY23 | $1.01 | n/a | $0.95 | |
| Q3 FY23 | −$0.01 | −102% | −$0.07 |
Against its peers
Companies in Drug Manufacturers - General nearest Siga Technologies' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SIGASiga Technologies | −$0.05 | −104% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| SPROSpero Therapeutics | $0.11 | |
| ABUSArbutus Biopharma | $0.78 | |
| Peer median | $0.78 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Siga Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.